| Title |
Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine
|
|---|---|
| Published in |
OncoTargets and therapy, July 2010
|
| DOI | 10.2147/ott.s5852 |
| Pubmed ID | |
| Authors |
Steven E McCormack, Erica D Warlick |
| Abstract |
Myelodysplastic syndromes (MDS) are a varied group of diseases leading to significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exert an effect on DNA methyltransferase leading to a reduction in DNA methylation, a process thought to be key to the pathogenesis of MDS. Recently, azacitidine has been shown to prolong survival and improve quality of life in patients with MDS, while maintaining a favorable adverse effect profile. This review highlights the scientific rationale for the use of azacitidine in addition to its application in current clinical practice for patients with MDS. |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 5% |
| Unknown | 21 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 18% |
| Student > Master | 4 | 18% |
| Other | 3 | 14% |
| Student > Bachelor | 2 | 9% |
| Lecturer > Senior Lecturer | 2 | 9% |
| Other | 4 | 18% |
| Unknown | 3 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 41% |
| Agricultural and Biological Sciences | 3 | 14% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Business, Management and Accounting | 1 | 5% |
| Nursing and Health Professions | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 5 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2022.
All research outputs
#5,446,994
of 25,374,647 outputs
Outputs from OncoTargets and therapy
#278
of 3,016 outputs
Outputs of similar age
#22,330
of 103,850 outputs
Outputs of similar age from OncoTargets and therapy
#1
of 5 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,850 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them